Geriatrics
Conference Coverage
Tau imaging predicts looming cognitive decline in cognitively normal elderly
BOSTON – Temporal lobe tau accumulation in cognitively normal older adults may be a good way of tracking Alzheimer’s disease progression.
Conference Coverage
Loneliness is common, and not just in the elderly
Age and disability status weren’t associated with increased risk for being lonely.
Conference Coverage
Head injury linked to amyloid deposition decades later
SAN DIEGO – Increased amyloid deposition found in the frontal cortex but not other areas associated with Alzheimer’s disease.
From the Journals
Up to 47 million Americans may have “preclinical” Alzheimer’s disease, study estimates
A primary prevention treatment that cut the risk of amyloidosis would sharply decrease this number, the modeling study found.
Conference Coverage
Retinal changes may reflect brain changes in preclinical Alzheimer’s
BOSTON – The retina could be “a window that could let us see what’s happening in the brain in early Alzheimer’s disease.”
Conference Coverage
Walking has beneficial cognitive effects in amyloid-positive older adults
BOSTON – Over 4 years, those who walked the most experienced the least cognitive decline.
Evidence-Based Reviews
Prescribing antipsychotics in geriatric patients: Focus on dementia
When to use SGAs for behavioral and psychological symptoms of dementia. Third of 3 parts.
Podcasts
Using antipsychotics for dementia
Helen C. Kales, MD, discusses risks and benefits of antipsychotics and other psychotropics for behavioral and psychological symptoms of dementia...
Conference Coverage
Intepirdine flops in phase 3 study of mild to moderate Alzheimer’s patients
BOSTON – But investigation continues in a phase 3 placebo-controlled study in patients with Lewy body dementia.
Video
MACRA Monday: Elder maltreatment screening
Screen an elderly patient for maltreatment and document a follow-up plan, if appropriate, and you could avoid a 4% MIPS penalty.
Conference Coverage
Long-term cholinesterase inhibition may slow cognitive decline – and more
BOSTON – New data suggest the drugs also reduce risk of heart attack, stroke, and all-cause mortality.